Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 18;14(2):310-316.
doi: 10.18240/ijo.2021.02.20. eCollection 2021.

Safety, effectiveness, and cost-effectiveness of Argus II in patients with retinitis pigmentosa: a systematic review

Zakieh Ostad-Ahmadi  1 , Amin Daemi  2 , Mohammad-Reza Modabberi  3 , Ali Mostafaie  4
Affiliations
Review

Safety, effectiveness, and cost-effectiveness of Argus II in patients with retinitis pigmentosa: a systematic review

Zakieh Ostad-Ahmadi et al. Int J Ophthalmol. .

Abstract

Aim: To assess the effectiveness, safety, and cost-effectiveness of the Argus II in treatment of the retinitis pigmentosa (RP) patients.

Methods: The ProQuest, Web of Science, EMBASE, MEDLINE (via PubMed) were searched using combinations of the keywords of Argus, safety, effectiveness, bionic eye, retinal prosthesis, and RP through March 2018. The retrieved records were screened and then assessed for eligibility.

Results: Totally 926 records were retrieved from the searched databases and finally 12 studies included. The RP patients showed improvements in visual function after receiving the prosthesis, compared to the time before the prosthesis or the time it was off. This was measured by square localization, direction of motion, and grating visual acuity tests. No major adverse effect was reported for the Argus II prosthesis itself and/or the surgery to implement it, but the most frequently reported items were hypotony, and conjunctival dehiscence. The incremental cost-effectiveness ratio (ICER) was calculated to be €14603 per quality-adjusted life year (QALY) in UK and $207 616 per QALY in Canada.

Conclusion: The available evidence shows that the Argus II prosthesis in RP patients is effective in improvement of their visual function. Some minor adverse effects are reported for the prosthesis. The cost-effectiveness studies show that the technology is cost-effective only at high levels of willingness-to-pay.

Keywords: Argus II; adverse; cost-effectiveness; effectiveness; retinal prosthesis; retinitis pigmentosa.

PubMed Disclaimer

Figures

Figure 1
Figure 1. PRISMA flow diagram for selection of studies on the safety, effectiveness and cost-effectiveness of the Argus II.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kang K, Tarchick MJ, Yu XS, Beight C, Bu P, Yu MZ. Carnosic acid slows photoreceptor degeneration in the Pde6brd10 mouse model of retinitis pigmentosa. Sci Rep. 2016;6:22632. - PMC - PubMed
    1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809. - PubMed
    1. Assistive Technology for Blindness and Low Vision. CRC Press; 2018. Low vision: types of vision loss and common effects on activities of daily life; pp. 77–98.
    1. Vaidya A, Borgonovi E, Taylor RS, Sahel JA, Rizzo S, Stanga PE, Kukreja A, Walter P. The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. BMC Ophthalmol. 2014;14:49. - PMC - PubMed
    1. Hahm BJ, Shin YW, Shim EJ, Jeon HJ, Seo JM, Chung H, Yu HG. Depression and the vision-related quality of life in patients with retinitis pigmentosa. Br J Ophthalmol. 2008;92(5):650–654. - PubMed

LinkOut - more resources